📰 Oncomap Extra News
Oncomap Extra News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Oncomap Extra. Real-time updates on events, politics, business and more.
January 8, 2023
Preliminary fourth quarter highlights: Expected total fourth quarter revenue, excluding COVID-19 testing, increased 28% compared to the fourth quarter 2021,...
January 8, 2023
Preliminary fourth quarter highlights: Expected total fourth quarter revenue, excluding COVID-19 testing, increased 28% compared to the fourth quarter 2021,...
December 9, 2022
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today shared initial clinical validation data...
December 7, 2022
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that new data presentations...
December 7, 2022
New independent clinical evidence from the pivotal TAILORx and RxPONDER trials support the role of the Oncotype DX Breast Recurrence Score test, the only genomic test to predict chemotherapy
December 6, 2022
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that new data presentations...
October 4, 2022
Ark launched a new fund on Sept. 27. While you try to figure it out, here are 7 cheap Cathie Wood stocks to buy for October.
September 8, 2022
In the signal-finding study currently enrolling colorectal and triple-negative breast cancer patients, the company will also evaluate the ability of its Xerna TME Panel to identify best responders.
August 21, 2022
Mirae Asset Global Investments Co. Ltd. raised its position in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 19.4% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 112,740 shares of the medical research company’s stock after buying an additional 18,357 shares during the quarter. Mirae Asset Global […]
August 2, 2022
Second quarter highlights Total second quarter revenue of $522 million, including Screening revenue of $354 million, Precision Oncology revenue of $154...